Abstract
Chronic fibrotic liver diseases such as viral hepatitis eventually develop liver cirrhosis, which causes occurrence of hepatocellular carcinoma (HCC). Given the limited therapeutic efficacy in advanced HCC, prevention of HCC development could be an effective strategy for improving patient prognosis. However, there is still no established therapy to meet the goal. Studies have elucidated a wide variety of molecular mechanisms and signaling pathways involved in HCC development. Genetically-engineered or chemically-treated experimental models of cirrhosis and HCC have been developed and shown their potential value in investigating molecular therapeutic targets and diagnostic biomarkers for HCC prevention. In this review, we overview potential targets of prevention and currently available experimental models, and discuss strategies to translate the findings into clinical practice.
Keywords: Animal model, chemoprevention, clinical trial, hepatocellular carcinoma, liver cirrhosis, prevention, bile duct ligation, carbon tetrachloride, connective tissue growth factor, direct acting antiviral, diethylnitrosamine, dimethylnitrosamine, extracellular matrix, epidermal growth factor, genetic hemochromatosis
Current Cancer Drug Targets
Title:Prevention of Hepatocellular Carcinoma: Potential Targets, Experimental Models, and Clinical Challenges
Volume: 12 Issue: 9
Author(s): Yujin Hoshida, Bryan C. Fuchs and Kenneth K. Tanabe
Affiliation:
Keywords: Animal model, chemoprevention, clinical trial, hepatocellular carcinoma, liver cirrhosis, prevention, bile duct ligation, carbon tetrachloride, connective tissue growth factor, direct acting antiviral, diethylnitrosamine, dimethylnitrosamine, extracellular matrix, epidermal growth factor, genetic hemochromatosis
Abstract: Chronic fibrotic liver diseases such as viral hepatitis eventually develop liver cirrhosis, which causes occurrence of hepatocellular carcinoma (HCC). Given the limited therapeutic efficacy in advanced HCC, prevention of HCC development could be an effective strategy for improving patient prognosis. However, there is still no established therapy to meet the goal. Studies have elucidated a wide variety of molecular mechanisms and signaling pathways involved in HCC development. Genetically-engineered or chemically-treated experimental models of cirrhosis and HCC have been developed and shown their potential value in investigating molecular therapeutic targets and diagnostic biomarkers for HCC prevention. In this review, we overview potential targets of prevention and currently available experimental models, and discuss strategies to translate the findings into clinical practice.
Export Options
About this article
Cite this article as:
Hoshida Yujin, C. Fuchs Bryan and K. Tanabe Kenneth, Prevention of Hepatocellular Carcinoma: Potential Targets, Experimental Models, and Clinical Challenges, Current Cancer Drug Targets 2012; 12 (9) . https://dx.doi.org/10.2174/15680096112091129
DOI https://dx.doi.org/10.2174/15680096112091129 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Future Oncotargets: Targeting Overexpressed Conserved Protein Targets in Androgen Independent Prostate Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Targeting Dopaminergic System for Treating Nicotine Dependence
Central Nervous System Agents in Medicinal Chemistry Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances
Current Pharmaceutical Design The Fallacy of the Longevity Elixir: Negligible Senescence May be Achieved, but Not by Using Something Physical
Current Aging Science Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
Protein & Peptide Letters Androgen Receptor Antagonists in the Treatment of Prostate Cancer
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) The Need for Improvement of the Treatment of Advanced and Metastatic Cervical Cancer, the Rationale for Combined Chemo-Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8
Anti-Cancer Agents in Medicinal Chemistry Induction of Apoptosis by Pierisin-6 in HPV Positive HeLa and HepG2 Cancer Cells is Mediated by the Caspase-3 Dependent Mitochondrial Pathway
Anti-Cancer Agents in Medicinal Chemistry Functional Nanogels for Biomedical Applications
Current Medicinal Chemistry Drug Metabolism and Pharmacokinetics of Dammarane Triterpenoids
Current Drug Metabolism Metal Complex-Peptide Conjugates: How to Modulate Bioactivity of Metal-Containing Compounds by the Attachment to Peptides
Current Medicinal Chemistry The Effects of 1,3,5-trisubstituted Indole Derivatives on Cell Growth, Apoptosis and MMP-2/9 mRNA Expression of MCF-7 Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Optimization of Time Controlled 6-mercaptopurine Delivery for Site- Specific Targeting to Colon Diseases
Current Drug Delivery Androgen Receptor Antagonists (Antiandrogens) Structure-Activity Relationships
Current Medicinal Chemistry Natural Monophenols as Therapeutics, Antioxidants and Toxins; Electron Transfer, Radicals and Oxidative Stress
The Natural Products Journal Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Targeting Cancer Stem Cell Lines as a New Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Polymeric Nanomicelles of Soluplus® as a Strategy for Enhancing the Solubility, Bioavailability and Efficacy of Poorly Soluble Active Compounds
Current Nanomedicine NF-κB in Anti-Inflammatory Activity of Probiotics: An Update
Current Immunology Reviews (Discontinued)